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Abstract
The recruitment of dendritic cells to sites of infections and their migration to lymph nodes is fundamental for antigen
processing and presentation to T cells. In the present study, we showed that antibody blockade of junctional adhesion
molecule C (JAM-C) on endothelial cells removed JAM-C away from junctions and increased vascular permeability after L.
major infection. This has multiple consequences on the output of the immune response. In resistant C57BL/6 and
susceptible BALB/c mice, we found higher numbers of innate immune cells migrating from blood to the site of infection.
The subsequent migration of dendritic cells (DCs) from the skin to the draining lymph node was also improved, thereby
boosting the induction of the adaptive immune response. In C57BL/6 mice, JAM-C blockade after L. major injection led to an
enhanced IFN-c dominated T helper 1 (Th1) response with reduced skin lesions and parasite burden. Conversely, anti JAM-C
treatment increased the IL-4-driven T helper 2 (Th2) response in BALB/c mice with disease exacerbation. Overall, our results
show that JAM-C blockade can finely-tune the innate cell migration and accelerate the consequent immune response to L.
major without changing the type of the T helper cell response.
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Introduction
Leishmania is an obligate intracellular parasite responsible for a
wide spectrum of clinical manifestations, such as cutaneous,
mucocutaneous or visceral leishmaniasis [1]. After inoculation of
Leishmania major in the skin of humans or rodents, promastigotes
are taken up by phagocytic cells [2]. The infection leads to the
development of cutaneous lesions, which eventually heal depend-
ing on the adaptive immune response of the host [3]. In the
C57BL/6 mouse model, resistance to L. major infection is
associated with the production of IFN-c by CD4+ Th1 lympho-
cytes [4,5]. The secretion of IFN-c by these Th1 cells then
activates infected macrophages, and leads to efficient killing of the
parasites [2,6]. Conversely, BALB/c mice mount a non-protecting
T helper 2 response (Th2) characterized by production of anti-
inflammatory cytokines such as IL-4, IL-10, and IL-13 [3,7].
Dendritic cells (DCs) are professional antigen-presenting cells
that play a key role in the induction of the adaptive immune
reaction against L. major. At early stages of infection in C57BL/6
mice, resident dermal DCs phagocytose the parasites [8] and
promote the switch towards a Th1 response by producing IL-12
[9]. Monocytes, subsequently recruited to the site of infection can
also give rise to monocyte-derived DCs (mo-DCs). During the late
phase of infection, such mo-DCs are essential mediators of the
protective T cell response. They efficiently migrate from the site of
infection to the draining lymph node, where they induce a specific
immune reaction against the pathogen [10]. The fundamental role
of monocytes and mo-DCs has been further highlighted with the
use of the CCR2 knock-out in the C57BL/6 background. In these
mice, the recruitment of mo-DC to the lymph nodes is severely
reduced, diminishing the Th1 cells [11], and resulting in a non-
healing phenotype similar to that observed in susceptible mice
[12]. Therefore, migration of DCs to the infected skin and lymph
node can be considered as fundamental steps towards immunity
against L. major.
Transendothelial migration of leukocytes from blood to the site
of inflammation is a complex process controlled by adhesion
molecules, such as PECAM-1, ICAM-2, ICAM-1, CD99, ESAM,
or junctional adhesion molecules (JAMs) [13]. The JAM family is
composed of 6 molecules comprising the classical JAM-A, JAM-B,
and JAM-C, mainly localized in the tight junctions of endothelial
cells [14]. In humans, JAM-C is also found on subpopulations of T
and B lymphocytes, and platelets [15,16], while murine JAM-C is
restricted to endothelial and stromal cells [17–19]. In the steady
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state, JAM-C mainly interacts with JAM-B [20] at cell-cell
contacts. Moreover, JAM-C and JAM-B can also bind the
integrins aMb2 (Mac-1) and a4b1 (VLA-4), respectively [16,21].
We previously described a monoclonal antibody raised against
mouse JAM-C, namely H33 [22]. H33 blocks JAM-C/JAM-B
interaction and redistributes JAM-C away from tight junctions
[20]. Interestingly, redistribution of JAM-C on the apical side of
endothelial cells makes it available for interactions with its counter-
receptor aMb2, an integrin found on neutrophils and monocytes,
therefore increasing their adhesion on endothelial cells [20]. More
recently, it was shown that H33 increases reverse and repeated
transmigration of monocytes and neutrophils, in mouse models of
peritonitis, and ischemia reperfusion injury, respectively [23,24].
However, the role of endothelial JAM-C in leukocyte migration in
the context of infectious disease was not addressed yet.
In this report, we studied the involvement of JAM-C in
leukocyte trafficking and the subsequent immune response against
L. major infection. We first observed that JAM-C expression by
vascular endothelial cells is down regulated after infection with L.
major at a time window when inflamed endothelium modulates
and redistributes its network of junctional proteins for leukocyte
transmigration [25]. To dissect the mechanism of JAM-C action in
this infectious disease model, we used the antibody H33 to mimic
the modulation of JAM-C observed after infection. Strikingly,
blocking JAM-C after L. major infection in vivo increased vascular
permeability and promoted leukocyte recruitment to the inflamed
tissue, and DC migration to the draining lymph node. More
importantly, sustained JAM-C blockade boosted the immune
response in both resistant C57Bl/6 and susceptible BALB/c mice.
On one hand, H33 treatment improved the IFN-c-dominated Th1
response in resistant animals, together with decreased lesion size
and parasite burden. On the other hand, JAM-C blockade boosted
the IL-4-dominated Th2 response in susceptible mice, resulting in
disease exacerbation. Collectively, our results show that JAM-C
blockade potentiates the immune responses to pathogen infections
by improving leukocyte migration.
Results
The antibody H33 mimics JAM-C downregulation after L.
major inoculation, and locally increases vascular
permeability after infection
Blood endothelial cells (BECs) and lymphatic endothelial cells
(LECs) from the skin of mouse ears were analyzed by flow
cytometry. In the steady state, BECs (CD452 CD31+ gp382) and
LECs (CD452 CD31+ gp38+) were JAM-C positive as previously
described for other organs [14] (Fig. 1A). Conversely, leukocytes
recruited to the infected ear following L. major inoculation were all
JAM-C negative (S1 Figure). We observed a statistically significant
decrease of JAM-C expression in BECs and LECs 24 hours after
L. major infection (Fig. 1A and B). This was not the consequence
of tissue injury caused by the needle, as saline injection did not
downregulate JAM-C (S2 Figure). Interestingly, previous studies
observed a peak of leukocytes migrating to the site of infection at
the same time period [26,27]. Therefore, we postulated that JAM-
C downregulation after infection could enhance vascular perme-
ability and therefore promote inflammation and cell migration.
To study the effect of H33 on vascular permeability, we used a
modified Miles assay in which mice were injected i.v. with Evan’s
blue [28]. Evan’s blue is a small molecule that binds strongly to
albumin. Consequently, this assay indirectly assesses the exudation
of plasma into the tissue accounting for vascular permeability.
Mice were treated with H33 or the isotype control antibody before
injection of Evan’s blue and L. major inoculation. Strikingly,
treatment with H33 significantly increased the amount of Evan’s
blue that leaked into the inflamed tissue as compared to control.
However, we did not observe any change in vascular permeability
under steady state conditions (Fig. 1C).
To understand the mechanism leading to the increased vascular
permeability, we investigated by immunofluorescence in our
system whether H33 redistributes JAM-C out of ear endothelial
cell junctions as previously proposed for other organs [20]. In
control mice, JAM-C was strongly expressed at the cell border of
CD31 positive endothelial cells (Fig. 1D, top panel), resulting in a
U-shaped pattern of distribution of the molecule (Fig. 1E, top
panel). In H33-treated animals however, JAM-C was removed
from endothelial cell junctions (Fig. 1D, bottom panel), as
confirmed by the smoothed pattern of distribution of JAM-C
(Fig. 1E, bottom panel). Control staining for JAM-C is provided in
S3 Figure.
Altogether, we concluded that the blockade of JAM-C with H33
redistributes JAM-C out of junctions, and increases vascular
permeability after L. major infection.
Blocking JAM-C increases the number of circulating cells
recruited in response to L. major infection
To study whether the effect of H33 on vascular permeability
potentiates leukocyte recruitment after L. major infection, we used
wild type C57BL/6 mice treated with H33, and analyzed by
FACS the number of emigrating leukocytes 24 hours after
infection (Fig. 2A). We observed a significant increase in the
numbers of neutrophils, inflammatory monocytes, and mo-DCs in
H33-treated animals as compared to control animals (Fig. 2B–D).
Meanwhile, the number of non-migrating dermal macrophages
(dermal mQ) was not modified (Fig. 2E). Finally, the number of
emigrating dermal DCs, a cell type that efficiently migrates to the
draining lymph node once activated, was decreased in H33-
treated animals (Fig. 2F). In line with the absence of vascular
permeability observed in the steady state (Fig. 1F), JAM-C
blockade did not increase leukocyte emigration in naı¨ve mouse
ears (S4 Figure). Moreover, we found no difference in the number
Author Summary
Leishmaniasis is a parasitic disease transmitted to humans
through sand fly bites. Clinical symptoms vary from self-
healing cutaneous lesions to death. Cutaneous leishman-
iasis is particularly studied in mice inoculated with
Leishmania major. In this model, some strains (e.g.
C57BL/6) are resistant due to a Th1 immune response
promoting parasite killing. Conversely, other strains (e.g.
BALB/c) are susceptible due to a nonprotective Th2
response. DCs are professional antigen-presenting cells
that educate antigen-specific T cells. Improving the
migration of DCs from the site of infection to the lymph
nodes, where T cells reside, may improve the T cell
response. JAM-C is a vascular adhesion molecule implicat-
ed in leukocyte migration in different inflammatory
models. We found that JAM-C blockade with antibodies
increases vascular permeability and consequently im-
proves the migration of DCs to sites of infection and
draining lymph nodes. This increased leukocyte migration
boosted the induction of the Th1 response in resistant
mice, while in susceptible mice the Th2 response was
augmented. This led to disease improvement or exacer-
bation, respectively. Our results illustrate the key role of a
vascular adhesion molecule in controlling leukocyte
migration and the subsequent immune events in response
to pathogen infections.
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of leukocytes in the bone marrow and in the blood (S5 Figure).
This suggests that H33 does neither increase haematopoiesis nor
leukocyte emigration from the bone marrow to the blood in
normal homeostasis.
We also measured higher levels of the monocytes and mo-DCs
attracting chemokine CCL3 in H33 treated animals early after
infection (Fig. 2G). This is in line with the increased number of
neutrophils, a cell type known to produce CCL3 to attract mo-
DCs in response to L. major [26]. Interestingly, the higher
numbers of innate immune cells recruited with H33 did not
impact on the parasite load early after infection (Fig. 2H and S6
Figure). Moreover, the dissemination of the parasites to the
draining lymph node was unchanged (Fig. 2I and S6 Figure).
Overall, our data showed that JAM-C blockade with H33
increases leukocyte recruitment to the site of infection, and
strongly suggest that H33 may influence DC migration to the
draining lymph node.
Blocking JAM-C increases the number of DCs migrating
to the draining lymph node
To investigate the effect of H33 on DC migration to the
draining lymph node, we used the FITC painting assay. In this
Fig. 1. The antibody H33 mimics JAM-C downregulation after L. major inoculation, and locally increases vascular permeability after
infection. (A) JAM-C levels in endothelial cells populations of mouse ear. Ears were enzymatically digested and stained for FACS analysis. CD452
CD31+ gp382 cells represent blood endothelial cells (BECs), whereas CD452 CD31+ gp38+ cells are lymphatic endothelial cells (LECs). For each
population, a representative histogram overlay is shown with JAM-C in endothelial cells from naı¨ve ears (black filled), JAM-C in endothelials cells from
L. major infected ears (blank filled), and the isotype control staining (grey filled). (B) The median fluorescence intensity (MFI) of JAM-C in naı¨ve mouse
ears (white bars) versus L. major infected mouse ears (black bars) was measured in BECs and LECs. The Y-axis scale represents MFI normalized to the
mean MFI of naı¨ve ears. Data represent the mean 6 SEM of ten individual mice pooled from two separate experiments, and were analyzed by the
unpaired Student’s t test with ***: p,0.001. (C) Mice were treated with H33 or control antibody 2 hours before Evans blue was injected i.v. and L.
major inoculated i.d. in the ear dermis. Skin permeability was assessed by the absorbance of Evans blue extracted from the sample normalized to the
weight of ear. Results are shown for naı¨ve versus L. major infected animals treated with H33 (black bars) or control antibody (blank bars).
Representative ear pictures are shown. Data represent the mean 6 SEM of seventeen mice per group pooled from two separate experiments, and
were analyzed by the unpaired Student’s t test with ***: p,0.001. (D) Ear sections from control antibody-treated (top panel) or H33-treated mice
(bottom panel) were stained for JAM-C (green) and CD31 (red). Nucleus was stained with DAPI (blue). Scale bars, 10 mm. Control staining for JAM-C is
shown in Figure S3. (E) The pixel intensity across 10 representative cells of similar size taken from three mice per group was measured and expressed
as a percentage of the maximal pixel intensity. Data represent the average profile plot for the 10 cells per group analyzed.
doi:10.1371/journal.ppat.1004550.g001
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model, migration of dermal and epidermal DCs to lymph nodes is
induced and peaks 18 hours after painting [29]. Based on MHC
class II (IA) and CD11c, two populations of DCs can be
distinguished by FACS in the lymph node: MHC-IIhigh CD11c+
migratory DCs, and MHC-II+ CD11chigh lymphoid resident DCs
(Fig. 3A). Strikingly, we found higher numbers of FITC+ IAhigh
CD11c+ migratory DCs in lymph nodes of H33-treated mice as
compared to control animals (Fig. 3A and B, and S7 Figure).
Therefore, H33 treatment not only increases leukocyte recruit-
ment to the site of infection, but also increases the migration of
DCs to the draining lymph node.
Blocking JAM-C improves the Th1 cell response and
favours healing in C57BL/6 mice
The increased DC migration to the draining lymph node in
mice treated with H33 raised the question of an eventual effect on
the subsequent T cell response and disease outcome. As previously
reported, the induction of the T cell response starts between the
second and third week after infection [10]. Therefore, mice were
infected with L. major and treated with H33 for 3 weeks in order
to boost DC migration and T cell activation. The disease was
followed weekly by measuring the area of the lesions, and we
assessed the L. major specific T cell response together with the
parasite burden 4 weeks and 8 weeks post infection (p.i.). In
C57BL/6 mice, we found smaller lesions in H33-treated
compared to control animals at both time points (Fig. 4A).
Moreover, the reduction of the lesion area between the groups
correlated with the decrease of the parasite load (Fig. 4B and S8
Figure). These results were in line with the increased numbers of
CD4+ and CD8+ T cells observed (Fig. 4C and D). More
importantly, draining lymph nodes T cells restimulated with
UV-irradiated L. major produced significantly higher levels of
IFN-c at 8 weeks post infection, which accounts for the reduced
lesion size and parasite load observed (Fig. 4E and S8 Figure).
Taken together, these data suggest that H33 increases DC
migration and therefore indirectly boosts the L. major specific
IFN-c-dominated Th1 cell response, resulting in a reduced
severity of the disease.
Blocking JAM-C boosts the Th2 cell response and
worsens the disease in BALB/c mice
Contrary to the C57BL/6 background, BALB/c mice develop a
Th2 response promoting susceptibility rather than resistance to L.
major infection [3]. Therefore, we investigated the effect of JAM-C
blockade on leukocyte migration and disease outcome in
susceptible BALB/c animals. After 24 hours of infection, we
Fig. 2. Blocking JAM-C increases the number of leukocytes recruited to the site of L. major infection. (A) Representative dot plots of
neutrophils (CD11b+ Ly6C+ Ly6G+); monocytes (CD11b+ Ly6C+ Ly6G2 CD11c2 IA2); mo-DCs (CD11b+ Ly6C+ Ly6G2 CD11c+ IA+); dermal mQ (CD11b+
Ly6C2 Ly6G2 CD11clow IA+); dermal DCs (CD11b+ Ly6C2 Ly6G2 CD11chigh IA+) in control versus H33-treated animals. (B–F) The number of neutrophils
(B), monocytes (C), mo-DCs (D), dermal mQ (E) and dermal DCs (F) was measured in the H33-treated (H33, black bar) versus isotype control-treated
mice (Ctr, white bars) 24 hours p.i. Data represent the mean 6 SEM of twenty mice per group pooled from 3 separate experiments, and were
analyzed by the unpaired Student’s t test with *: p,0.05 and **: p,0.01. (G) CCL3 protein levels normalized to the weight of ears were measured in
H33-treated (H33, black bar) versus isotype control-treated mice (Ctr, white bars) 8 and 24 hours p.i. Data represent the mean 6 SEM of ten mice per
group pooled from 2 separate experiments, and were analyzed by the unpaired Student’s t test with **: p,0.01. (H–I) The parasite burden in infected
ears (H) and draining lymph nodes (LN) (I) were measured 48 hours p.i. by limiting dilution assay (LDA). Data are expressed as a percentage of the
mean of the control group 6 SEM of ten mice per group pooled from 2 separate experiments, and were analyzed by the unpaired Student’s t test.
For panel H and I, raw data of one representative experiment are provided in S6 Figure.
doi:10.1371/journal.ppat.1004550.g002
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found increased numbers of neutrophils, and mo-DCs recruited to
the site of infection in H33-treated BALB/c mice as compared to
isotype control-treated mice (Fig. 5A and B). Moreover, we
observed a decreased number of dermal DCs while unchanged
numbers of dermal macrophages (Fig. 5C and D). These results
showed that H33 influences leukocyte migration in a similar
manner in BALB/c than in C57BL/6 mice. We next wanted to
assess whether this increased leukocyte migration could change the
dominance of the Th2 response over the Th1 response along the
course of the disease. To this end, BALB/c mice were injected
with the same dose of L. major used with C57BL/6 mice. We did
not find any change in the disease outcome with H33, most likely
Fig. 3. Blocking JAM-C increases the number of DCs migrating to the draining lymph node. (A) The ear draining lymph node cells were
harvested and stained for FACS analysis 18 hours after FITC-painting. Representative FACS dot plots are shown. (B) The number of IAhigh CD11c+
FITC+ migratory DCs was counted. Data are expressed as a percentage of the mean of the control group 6 SEM of eighteen mice per group pooled
from 3 separate experiments, and were analyzed by the unpaired Student’s t test with ***: p,0.001. Raw data from one representative experiment
are provided in S7 Figure.
doi:10.1371/journal.ppat.1004550.g003
Fig. 4. Blocking JAM-C improves the Th1 cell response and favours healing in C57BL/6 mice. (A–E) Mice were inoculated with L.
major in the ear dermis and treated with H33 or isotype control antibody for 3 weeks, twice a week. (A) The area of the lesion was
monitored weekly and representative pictures of ear lesions are shown at 4 and 8 weeks p.i. Scale bars, 0.5 mm. Data represent the mean 6 SEM of
twenty mice per group pooled from two separate experiments for the time point 4 weeks; and fifteen mice per group pooled from two separate
experiments for the time point 8 weeks. (B) The parasite burden in infected ears was measured by LDA 4 and 8 weeks p.i. Data are expressed as a
percentage of the mean of the control group 6 SEM of mice from panel A. (C–D) The number of draining lymph node CD4+ (C) and CD8+ (D) T cells
analyzed by flow cytometry 4 and 8 weeks p.i. Data represent the mean6 SEM of mice from panel A. (E) Draining lymph node cells were restimulated
for 72 hrs with UV-irradiated L. major and the secreted IFN-c was measured. Data are expressed as a percentage of the mean of the control group 6
SEM of mice from panel A. Data were analyzed by the unpaired Student’s t test with *:p,0.05 and **: p,0.01. For panels B and E, raw data from one
experiment are also provided in S8 Figure.
doi:10.1371/journal.ppat.1004550.g004
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as a result of an exaggerated Th2 polarization with high parasite
doses (Fig. 5E). Therefore, we designed a new experiment with
200 fold less parasites inoculated. Strikingly, we now observed
higher lesions in H33-treated animals (Fig. 5F). This correlated
with increased parasite loads in ears and draining lymph nodes
(Fig. 5G and H), while parasites were undetectable in spleens (S9
Figure). The number of T cells was also augmented in draining
lymph nodes (Fig. 5I and J) and they secreted higher levels of IL-4
upon restimulation with UV-irradiated L. major (Fig. 5K). The
production of IFN-c was however unchanged (Fig. 5L). Altogeth-
er, these results show that the increased DC migration boosts the
polarized Th2 immune response without changing the type of the
T helper cell response.
Discussion
In this study we investigated the involvement of JAM-C in the
immune response against L. major. We first observed a decreased
cell surface expression of endothelial JAM-C that corroborated
with the strong accumulation of leukocytes at the site of L. major
infection. We therefore postulated that JAM-C downregulation
would render the endothelial junctions more permeable for
inflammatory cells or fluids.
Previous findings reported that JAM-C mainly stabilizes cell
junctions through trans-heterophilic, high affinity, low turnover
interactions with its main partner JAM-B, while homophilic JAM-
C-JAM-C interactions are weaker and occur with rapid dynamics
[20]. The function of JAM-C in regulating endothelial permeabil-
ity has been addressed by in vivo and in vitro studies using
different approaches. In vitro, we have previously reported that
CHO cells transfected with JAM-C exhibit an increased barrier
function while MDCK cells transfected with JAM-C present
increased paracellular permeability [22,30]. When HUVEC cells
were stimulated with the permeability factors VEGF or thrombin,
JAM-C redistributed rapidly into cell-cell contacts and permeabil-
ity was augmented [31,32]. Overexpression of JAM-C in vitro also
renders endothelial cells more permeable, probably due to the
association in cis with the integrin avb3 [32]. These findings
strongly suggest that the integrity of the endothelium is the result
of a finely regulated ratio of junctional molecules. Moreover, one
should also consider that overexpression of JAM-C in such in vitro
systems may interfere with the biogenesis of endogenous junctional
proteins with unpredictable consequences for the barrier function
[33]. More recently, Chavakis and coworkers addressed the
permeability question by using wild type mice treated with soluble
recombinant JAM-C in a histamine-mediated vascular permeabil-
ity model [34]. They reported that soluble JAM-C reduces
vascular permeability in this particular model. It is worth noting
that soluble JAM-C binds to JAM-C but can also engage strong
interactions with JAM-B, or with other unknown ligands.
Therefore, the effect of soluble JAM-C may be the sum of several
interactions, making interpretation of these results difficult.
To specifically address the function of JAM-C in vascular
permeability in vivo, we used the multi-faceted H33 antibody that
blocks JAM-C-JAM-B interactions and redistributes JAM-C out of
tight junctions [20]. In our model, we were able to confirm that
H33 removes JAM-C out from endothelial cell junctions. More
importantly, this study showed for the first time that JAM-C
blockade and redistribution with H33 increases vascular perme-
ability by 15% after L. major inoculation in the skin. Conversely,
we did not observe increased vascular permeability after admin-
istration of H33 in the steady state. This increase is substantial, as
vascular permeability in inflammation is an optimized process
[35]. Moreover, the absence of the H33 effect on vascular
permeability in normal homeostasis is not surprising as many other
different junctional molecules can still ensure vascular integrity in
absence of inflammatory signals [36]. In line with this observation,
H33 treatment also does not increase leukocyte migration from the
blood to the tissue in absence of pathogen-mediated, inflammatory
signals. However, after L. major infection, the number of
leukocytes that migrate to the inflamed tissue increased signifi-
cantly in mice treated with H33. As recent findings showed that
VE-cadherin controls permeability and transmigration indepen-
dently [37], our data with H33 may be in part the result of
increased vascular permeability or the redistribution of JAM-C
away from junctions as well. Redistribution of JAM-C on the
apical side of the lumen makes it available for interactions with
Mac-1 found on neutrophils and monocytes [20]. Accumulation of
more adherent leukocytes on the luminal side of vessels could then
increase the number of transmigrating cells. Therefore, H33 may
increase leukocyte adhesion to the inflamed endothelium in
addition to promoting vascular permeability in the context of L.
major infection (Fig. 6).
In the L. major mouse model of cutaneous leishmaniasis, the
kinetics of leukocyte recruitment, their specific function, and the
crosstalk between the different subsets of cells have been and are
still under investigation. It is now well accepted that neutrophils
are the first cells recruited within hours to the infected tissue
[10,27,38,39]. However, some discrepancies still exist concerning
their immunoregulatory function, which may depend on the mode
of parasite transmission and the number of pathogens inoculated.
Indeed, in the Leishmania resistant C57BL/6 mice, Sacks and
coworkers used the monocyte and neutrophil depleting RB8-6C5
antibody and a natural sand-fly transmission of L. major to show
that depletion of these cells promotes rather than compromises
host resistance [38]. More recently, they showed that efferocytosis
of infected neutrophils by DCs decreases their activation and
antigen presenting cell function, therefore dampening the protec-
tive pro-inflammatory response [27]. On the other hand, other
reports using needle inoculation of high parasite doses like our
study, have demonstrated a transient protective role for neutro-
phils in C57BL/6 mice [40–42]. These studies assessed the role of
neutrophils mostly by depletion, mediated by the more neutrophil-
specific antibody NIMP-R14 [39] or by the anti-Gr1 RB6-8C5
antibody recognizing inflammatory monocytes and neutrophils.
All these neutrophil depletion studies resulted in transient
increased lesion size and parasite loads. It is worth noting that
RB6-8C5, the antibody used in most of the studies, not only
depletes neutrophils but also inflammatory monocytes, illustrating
the importance of neutrophils and inflammatory monocytes in
promoting resistance to infection. The contribution of monocytes
and mo-DCs has been further investigated with the use of
chemokine receptor CCR2 knock-out mice in the resistant
C57BL/6 background. In these mice, monocytes do not leave
the bone marrow, resulting in a deficiency of monocytes in the
blood circulation [43]. The recruitment of inflammatory mo-DCs
in the lymph node following L. major infection is therefore
completely impaired, which dampens the Th1 cell response [11].
Subsequently, the CCR2 deficiency results in a non-healing
phenotype similar to that observed in susceptible mice [12]. Our
report is in line with these studies, as treatment with the antibody
H33 increased the recruitment of neutrophils, inflammatory
monocytes and mo-DCs, and thereby improving the Th1 immune
response and the clinical outcome in C57BL/6 mice. In addition,
Tacchini-Cottier and coworkers [26] emphasized the contribution
of neutrophils in the recruitment of mo-DCs to the site of L. major
infection through the secretion of the chemokine CCL3. In line
with this finding, we observed a significant increase in the
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Fig. 5. Blocking JAM-C boosts the Th2 cell response and worsens the disease in BALB/c mice. The number of emigrating neutrophils (A),
mo-DCs (B), dermal DCs (C) and dermal mQ (D) was measured in the ears of H33-treated (H33, black bar) versus isotype control-treated mice (Ctr,
white bars) 24 hours post L. major infection. Data represent the mean 6 SEM of twelve mice per group pooled from 2 separate experiments, and
were analyzed by the unpaired Student’s t test with *: p,0.05. (E) Mice were inoculated with 26106 stationary phase L. major promastigotes in the
ear dermis and treated with H33 or control antibody for 3 weeks. The area of the lesion was monitored weekly for 6 weeks. Representative ear
pictures are shown. Scale bars, 1 mm. Data represent the mean 6 SEM of twenty mice per group pooled from two separate experiments. (F–L) Mice
were inoculated with 16104 stationary phase L. major promastigotes in the ear dermis and treated with H33 or control antibody for 3 weeks. The area
of the lesion was monitored weekly for 4 weeks. Representative ear pictures are shown. Scale bars, 0.5 mm. Data represent the mean 6 SEM of ten
mice per group pooled from two separate experiments. (G–H) The parasite burden in infected ears (G) and draining lymph nodes (H) were measured
by LDA. Data are expressed as a percentage of the mean of the control group6 SEM of mice from panel F. (I–J) The number of CD4+ (I) and CD8+ (J) T
cells were measured. Data represent the mean 6 SEM of mice from panel F. (K–L) Draining lymph nodes cells were restimulated with UV-irradiated L.
major for 72 hours, and the IL-4 (K) and IFN-c (L) produced were measured. Data are expressed as a percentage of the mean of the control group 6
SEM of mice from panel F. Data were analyzed by the unpaired Student’s t test with *:p,0.05 and **: p,0.01. For panels expressing results as a
percentage of the mean of the control, raw data of one experiment are provided in S9 Figure.
doi:10.1371/journal.ppat.1004550.g005
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production of CCL3 within ears of H33 treated mice at time
points where neutrophils are massively recruited to the site of
infection. Therefore, we suggest that, by increasing the numbers of
neutrophils recruited, H33 could indirectly increase the amount
of CCL3 produced in situ. This additional mechanism may also
contribute to further enhance the extravasation of mo-DCs in the
ears of H33 treated C57BL/6 mice (Fig. 6).
We also report that H33 increases the number of DCs leaving
the ear dermis to the draining lymph node. This may be the direct
consequence of JAM-C blocking at lymphatic endothelial cell
junctions, which would facilitate DCs transendothelial migration.
Alternatively, it could be the indirect consequence of the higher
number of DCs recruited to the site of inflammation that migrate
to the lymph node as a consequence. The later hypothesis is more
likely since DCs preferentially migrate in an integrin-independant
manner through initial lymphatic capillaries by seeking pre-
existing flaps between the oak leaf-shaped lymphatic endothelial
cells [44,45]. It is worth noting that JAM-C is also well expressed
by lymphatic sinuses from lymph nodes, which may influence T
cell surveillance of DCs in the lymph nodes, and therefore T cell
activation after H33 treatment. However, we had already
demonstrated that the ability of DCs to prime T cells in vivo in
JAM-C deficient animals is unchanged [46]. In lymph nodes,
JAM-C is also expressed by high endothelial venules, and we
cannot exclude an effect of H33 on T cell entry into lymph nodes.
Finally, we used the properties of H33 treatment on vascular
permeability and innate cell migration to assess the consequences
on the clinical outcome. In C57BL/6 mice, the higher numbers of
neutrophils or monocyte-derived cells recruited rapidly after
infection may increase the early innate parasite killing. However,
we observed no difference in the parasite load 48 hours after
infection. This is likely due to the absence of the IFN-c-dominated
Th1 response that leads to activation of phagocytes and parasite
killing at this early time point [3]. Moreover, the increased
vascular permeability at the site of infection may have influenced
the dissemination of the parasite to peripheral organs early after
infection. But we did not found any change in the draining lymph
nodes, while the parasite was undetectable in spleen. Strikingly, we
found that H33 was able to boost the adaptive immune response in
both susceptible and resistant mice by increasing DC migration,
without changing the T cell polarization. This report is the first
one to demonstrate that immune responses to pathogen infections
can be finely-tuned by manipulating a single adhesion molecule,
and in particular JAM-C. For instance, deletion of P- or E-selectin
does not impact the immune response to L. major infection in a
mixed 129/C57BL/6 background [47]. Finally, our findings in
BALB/c mice confirm that susceptibility does not result from an
overall lack of leukocyte migration to the site of infection, but
rather from a genetic defect in redirecting the T cell response [3].
Materials and Methods
Ethics statement
All animal procedures were performed in accordance with the
Institutional Ethical Committee of Animal Care in Geneva,
Switzerland. The protocol has been approved by the Ethics and
Federal Veterinary office regulations of the state of Geneva. Our
laboratory has the authorization number 1005-3753.1.
Mice and parasites
Female C57BL/6J and BALB/c mice were purchased from
Charles River (Lyon, France). Mice were bred in the P2 animal
facility at the CMU, and used between 6–8 weeks of age.
Leishmania major LV39 (MRHO/Sv/59/P Strain) were used. In
all experiments, C57BL/6 mice were infected in the ear dermis
with 26106 stationary phase L. major promastigotes in a volume of
10 mL. The disease outcome in BALB/c was followed after
infection with 26106 and 16104 stationary phase L. major
promastigotes in a volume of 10 mL.
Flow cytometry analysis of ear endothelial cells
The ventral and dorsal sheets of mouse ears were split with
forceps, and digested with 3 mg/mL collagenase type IV
(Invitrogen) and 1 mg/mL DNAse type I (Sigma Aldrich) for
Fig. 6. Blocking JAM-C enhances DC migration and boosts the immune responses to L. major infection. By removing JAM-C out of
functions, H33 increases adhesion of leukocytes and potentiates vascular permeability and cell migration of leukocytes after L. major infection.
Increased numbers of recruited neutrophils result in higher levels of the chemokine CCL3 attracting monocytes and mo-DCs in C57BL/6 mice. The
number of migratory DCs to lymph nodes increases, and the subsequent T cell response is mounted more efficiently. Resistant C57BL/6 mice develop
a higher IFN-c-dominated Th1 response while susceptible BALB/c mice develop a stronger IL-4-dominated Th2 response. This has a significant
healing effect in resistant animals whereas susceptible mice display an exacerbated disease.
doi:10.1371/journal.ppat.1004550.g006
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45 minutes at 37uC, filtered through a 70 mm gauge strainer
(Becton Dickinson), and the cells labelled for FACS analysis. Fc
receptors were blocked with the monoclonal antibody (mAb)
2.4G2 (Becton Dickinson). Cells were stained with the following
reagents: Alexa Fluor 488-conjugated anti-mouse podoplanin
(clone 8.1.1), PE-conjugated anti-mouse CD31 (clone 390), PE-
Cy7-conjugated anti-mouse CD45 (clone 30-F11), all from
affimetrix eBioscience. JAM-C was labelled with an affinity
purified polyclonal anti-mouse JAM-C antibody raised in rabbit
[31], while affinity purified rabbit IgG (Sigma) was used as a
control. The secondary antibody used was an Alexa Fluor 647-
conjugated anti-rabbit antibody (Jackson ImmunoResearch). Cells
were analyzed with a Gallios FACS machine (Beckman Coulter)
and the data were processed with Kaluza software (Beckman
Coulters).
Leukocyte emigration for ear skin explants and FACS
analysis
Mice were injected i.p. with the rat IgG2a anti-mouse JAM-C
H33 or the rat IgG2a isotype control 2A3 (BioXCell), 200 mg/
mice, 2 hours before inoculation of L. major in the ear dermis.
Twenty-four hours post infection, mice were sacrificed and ears
explanted. The ventral and dorsal sheets of the ears were
separated with forceps, and transferred overnight in twelve well
plates filled with RPMI-1640 medium supplemented with 10%
fetal calf serum and antibiotics at 37uC. Over this period of time,
the leukocytes that have been recruited to the infected ears
spontaneously emigrated from the explants. Emigrated cells were
then counted with a hemocytometer, and stained for FACS
analysis. Fc receptors were blocked with the mAb 2.4G2. Cells
were stained with the following reagents: Alexa Fluor 488-
conjugated anti-mouse Ly6C (clone HK1.4, Biolegend), PercP-
Cy5.5-conjugated anti-mouse Ly6G (clone 1A8, Biolegend), PE-
Cy7-conjugated anti-mouse CD11b (clone M1/70, Biolegend),
APC-Cy7-conjugated anti-mouse CD11c (clone N418, Biolegend),
and efluor 450-conjugated anti-mouse IA/IE (clone M5/114.15.2,
eBiosciences). Cells were analyzed with a Gallios FACS machine
(Beckman Coulter) and data processed with Kaluza software
(Beckman Coulters). The number of cells per population was
calculated by multiplying the total number of emigrating cells with
the percentage of cells of interest.
FACS analysis of leukocyte populations in steady state
Mice were injected i.p. with the mAb H33 or the control mAb
2A3 (200 mg/mice). Mice were then sacrificed 24 hours after
treatment to collect ears, blood and femurs. Ears were processed as
described above. Femurs were flushed to extract bone marrow
cells. Red blood cells from blood and bone marrow samples were
lysed with Ammonium-Chloride-Potassium (ACK) lysis buffer. A
fraction of each sample was used for FACS staining using BD
Trucount tubes according to the manufacturer’s instructions. Fc
receptors were blocked with the mAb 2.4G2. Bone marrow cells
were stained with the following reagents: Alexa Fluor 488-
conjugated anti-mouse Ly6C (clone HK1.4, Biolegend), PE-
conjugated anti-mouse CD115 (clone AFS98, eBiosciences),
PercP-Cy5.5-conjugated anti-mouse Ly6G (clone 1A8, Biolegend),
PE-Cy7-conjugated anti-mouse F4/80 (clone BM8, Biolegend),
APC-conjugated anti-mouse CD11c (clone HL3, BD), APC-Cy7-
conjugated anti-mouse TCRb (clone H57-597, Biolegend), efluor
450-conjugated anti-mouse CD11b (clone M1/70, eBiosciences),
Brilliant Violet 785-conjugated anti-mouse CD8a (clone 53-6.7,
Biolegend). Blood cells were stained with the following reagents:
Alexa Fluor 488-conjugated anti-mouse Ly6C (clone HK1.4,
Biolegend), PE-conjugated anti-mouse CD115 (clone AFS98),
PercP-Cy5.5-conjugated anti-mouse Ly6G (clone 1A8, Bio-
legend), PE-Cy7-conjugated anti-mouse CD4 (clone RM4-5,
Biolegend), APC-conjugated anti-mouse NK1.1 (clone PK136,
Biolegend), APC-Cy7-conjugated anti-mouse CD19 (clone 6D5,
Biolegend), efluor 450-conjugated anti-mouse CD11b (clone M1/
70, eBiosciences), Brilliant Violet 785-conjugated anti-mouse
CD8a (clone 53-6.7, Biolegend). Cells were analyzed with a
Gallios FACS machine (Beckman Coulter) and the data were
processed with Kaluza software (Beckman Coulter). The number
of cells per population was calculated by multiplying the total
number of cells with the percentage of cells of interest. The total
number of cells was calculated using the number of Trucount
beads analyzed by the flow cytometer.
FITC painting experiments
Mice were injected i.p. with the mAb H33 or the control mAb
2A3 (200 mg/mice) 2 hours before FITC painting of mice ears.
FITC (Sigma) was used at 5 mg/mL and dissolved in aceton:
dibutyl phthalate (1:1, v:v). Twenty microliters were applied to
each side of the ear. Eighteen hours after painting, the ear draining
lymph node was harvested and digested with 3 mg/mL collage-
nase type IV (Invitrogen) and 1 mg/mL DNAse type I (Sigma) for
459 at 37uC, and filtered through a 70 mm gauge strainer (Becton
Dickinson). The cells were counted with a hemocytometer, and
labelled for FACS analysis. Fc receptors were blocked with the
mAb 2.4G2. Cells were stained with the following reagents: APC-
Cy7-conjugated anti-mouse CD11c, and efluor 450-conjugated
anti-mouse IA/IE. Cells were analyzed with a Gallios FACS
machine (Beckman Coulters) and data processed with Kaluza
software (Beckman Coulters). The number of FITC+ migratory
DCs was calculated by multiplicating the total number of lymph
node cells with the percentage of IA/IEhigh CD11c+ FITC+ DCs.
Immunofluorescence microscopy
Mice were injected i.p. with the mAb H33 or the control mAb
2A3 (200 mg/mice). Twenty-four hours after injection, ears were
embedded in Tissue-Tek OCK compound, frozen at 280uC, then
cut (5 mm) with a cryostat. Fresh ear sections were fixed in cold
acetone for 5 minutes, rehydrated in PBS for 10 minutes, and
blocked with 10% normal donkey serum. CD31 was detected with
an Alexa Fluor 647-conjugated rat anti mouse CD31 (clone GC51,
home made), while JAM-C was detected with a polyclonal anti-
mouse JAM-C antibody raised in rabbit [31] followed by an Alexa
Fluor 488-conjugated donkey anti-rabbit antibody (Jackson
ImmunoResearch). We used rabbit IgG as control for JAM-C
staining. Cell nucleus was stained with DAPI and slides were
mounted with mowiol mounting medium. Labelled ear sections
were visualized with a Nikon A1R confocal microscope and the
NIS Elements AR software. All images were acquired with a 1006
objective. The maximal intensity projection image of the z-stack is
shown. The images were analyzed with Image J. The distribution
profile of JAM-C was ploted along the minor axis of the cells.
Vascular permeability assay
Mice were treated i.p. with the mAb H33 or the control mAb
2A3 (200 mg/mice) 2 hours before 100 mL of Evans blue (12 mg/
mL) was injected i.v. and L. major inoculated i.d. in the ear. Five
hours after infection, mice were killed, and the permeability of
Evans blue in the ear documented by picturing each ear. Ears
were then cut, weighted, split into dorsal and ventral sheets, and
finally transferred into formamide for 2 days at room temperature
to extract the Evans blue dye. The absorbance of the samples was
measured at 620 nm (Ledetect 96, Labexim) and normalized to
the weight of tissue.
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CCL3 level in ear following L. major infection
Mice were injected i.p. with H33 or the control mAb 2A3
(200 mg/mice) 2 hours before L. major inoculation in the ear
dermis. Eight or 24 hours after infection, ears were homogenized
on ice in a protease inhibitor cocktail (Sigma Aldrich, P8340) using
a polytron as tissue homogenizer. The expression of the
chemokine CCL3 were measured in tissue homogenates with the
BD CBA mouse Flex Set kit according to the manufacturer
instructions. Beads were analyzed on a Cyan (Beckman Coulters)
flow cytometer and data processed with the FCAP array software
(Becton Dickinson).
T cell response in the draining lymph node and cytokine
detection
The ear draining lymph nodes were digested with 3 mg/mL
collagenase type IV (Invitrogen) and 1 mg/mL DNAse type I
(Sigma) for 459 at 37uC, and filtered through a 70 mm gauge
strainer (Becton Dickinson). The cells were counted with a
hemacytometer and labelled for FACS analysis. Fc receptors were
blocked with the mAb 2.4G2. Cells were stained for cell surface
antigens with the following reagents: FITC-conjugated anti-mouse
TCRb (clone H57-597, eBioscience), Brilliant Violet 421-conju-
gated anti-mouse CD8a (clone 53-6.7, Biolegend), Brilliant Violet
785-conjugated anti-mouse CD4 (clone RM4-5, Biolegend). Cells
were analyzed with a Gallios FACS machine (Beckman Coulters)
and the data were processed with Kaluza software (Beckman
Coulters). The number of cells per population was calculated by
multiplying the total number of lymph nodes cells with the
percentage of cells of interest. For T cell restimulation, draining
lymph nodes cells were incubated at 37uC under 5% CO2 for
72 hours in the presence of UV-irradiated L. major (ratio 5:1,
cell:parasite). Supernatant were collected and the levels of IL-4
and IFN-c were measured by ELISA (eBioscience) or CBA
(Becton Dickinson) according to the manufacturer instructions.
Lesion area measurement and parasite load
Mice were injected i.p. with the mAb H33 or the control mAb
2A3 (200 mg/mice) 2 hours before inoculation of L. major in the
ear dermis. Injections of mAbs (100 mg/mice) were repeated twice
a week for twenty-one days. The evolution of the lesion was
documented weekly with a picture of each ear, as well as the
picture of a 1 cm scale. The camera was fixed on a support for the
scale to be unchanged from one picture to the other. The pictures
were analyzed with ImageJ software. Briefly, the picture of the
1 cm scale provides the number of pixels per 1 cm unit. Each
lesion was then defined manually with the software, and the
precise lesion area calculated using the number of pixels in the
selected area. For parasite burden, the infected ears were
explanted, weighted, and separated into two halves. Ear leaflets
were enzymatically digested before tissue dissociation with a
gentleMACS Octo Dissociator (Miltenyi Biotech). Ears homoge-
nates, lymph nodes or spleens cells were serially diluted, and the
parasite load estimated by limiting dilution assay as described [48].
Statistical analysis
Data were analyzed with the GraphPad Prism statistics
software. We used the Student’s t-test for unpaired data for all
experiments.
Supporting Information
Figure S1 Leukocytes emigrating to the site of L. major
infection do not express JAM-C. The expression of JAM-C by
leukocytes emigrated from L. major infected ears was measured
24 hours post infection. CD11b+ Ly6C+ Ly6G+ represent
neutrophils, CD11b+ Ly6C+ Ly6G2 CD11c2 IA2 are monocytes,
CD11b+ Ly6C+ Ly6G2 CD11c+ IA+ are mo-DCs, CD11b+
Ly6C2 Ly6G2 CD11clow IA+ are dermal mQ, and CD11b+
Ly6C2 Ly6G2 CD11chigh IA+ are dermal DCs. A representative
histogram overlay of JAM-C expression is shown for each
population, with JAM-C staining (black line), and isotype control
staining (grey line). Data are representative of two separate
experiments.
(TIFF)
Figure S2 JAM-C expression in ear endothelial cells
does not decrease 24 hours after saline injection (A)
JAM-C levels in endothelial cells populations of mouse
ear. Ears were enzymatically digested and stained for FACS
analysis. CD452 CD31+ gp382 cells represent blood endothelial
cells (BECs), whereas CD452 CD31+ gp38+ cells are lymphatic
endothelial cells (LECs). For each population a representative
histogram overlay is shown with JAM-C in endothelial cells from
naı¨ve ears (white filled), JAM-C in endothelial cells from saline
injected ears (black filled), and the isotype control staining (grey
filled). (B) The MFI of JAM-C in naı¨ve mouse ears (white bars)
versus saline injected mouse ears (black bars) was measured in
BECs and LECs. The Y-axis scale represents MFI normalized to
the mean MFI of naı¨ve ears. Data represent the mean 6 SEM of
five mice per group pooled from two separate experiments.
(TIFF)
Figure S3 Control staining for JAM-C in ear endothelial
cells. Ear sections were stained for Rabbit IgG control (green),
CD31 (red). Nucleus was stained with DAPI (blue). Scale bars,
10 mm. This supporting information is related to Fig. 1D.
(TIFF)
Figure S4 Blocking JAM-C does not result in leukocyte
emigration to tissue in the steady state. The number of
neutrophils (A), monocytes (B), mo-DCs (C), dermal mQ (D), and
dermal DCs (E) emigrating from ears was measured in H33-
treated (H33, black bar) versus isotype control-treated mice (Ctr,
white bars) 24 hours after antibody administration. Data represent
the mean6 SEM of fifteen mice per group pooled from 3 separate
experiments, and were analyzed by the unpaired Student’s t test.
(TIFF)
Figure S5 Blocking JAM-C in the steady state does
neither increase hematopoiesis nor leukocyte migration
from bone marrow to the blood. Naı¨ve C57BL/6 mice were
treated with H33 or isotype control antibody for 24 hours. The
number of neutrophils (A), monocytes (B), DCs (C), T cells (D),
eosinophils (E), and macrophages (F) from the bone marrow (BM);
and B cells (G), CD4+ T cells (H), CD8+ T cells (I), neutrophils (J),
monocytes (K), and NK cells (L) from blood in H33-treated (black
bar) versus isotype control-treated mice (white bars) is shown. Data
represent the mean 6 SEM of five mice per group, and were
analyzed by the unpaired Student’s t test. Data are representative
of three separate experiments.
(TIFF)
Figure S6 H33 antibody does neither decrease the
parasite burden in infected ears, nor increase parasite
dissemination to lymph nodes 48 hours p.i. (Raw data of
Fig. 2). The parasite burden in infected ears (A) and draining lymph
nodes (B) were measured 48 hours p.i. by LDA. Data represent the
mean 6 SEM of five mice per group from one representative
experiment, and were analyzed by the unpaired Student’s t test.
These supporting informations are related to Fig. 2H and I.
(TIFF)
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Figure S7 Blocking JAM-C increases the number of DCs
migrating to the draining lymph node (Raw data of
Fig. 3). The ear draining lymph nodes were harvested and
stained for FACS analysis 18 hours after FITC-painting. The
number of IAhigh CD11c+ FITC+ migratory DCs was counted.
Data represent the mean 6 SEM of six mice per group, and were
analyzed by the unpaired Student’s t test with *: p,0.05. This
supporting information is related to Fig. 3B.
(TIFF)
Figure S8 Blocking JAM-C improves the Th1 cell
response and favours healing in C57BL/6 mice (Raw
data of Fig. 4). Mice were inoculated with L. major in the ear
dermis and treated with H33 or the isotype control antibody for 3
weeks, twice a week. (A) The parasite burden in infected ears was
measured by LDA 4 and 8 weeks p.i. Data represent mean 6
SEM of ten mice per group for both time points. (B) Draining
lymph node cells were restimulated for 72 hrs with UV-irradiated
L. major and the secreted IFN-c was measured. Data represent the
mean 6 SEM of mice from panel A. Data were analyzed by the
unpaired Student’s t test with *:p,0.05. These supporting
informations are related to Fig. 4B and E.
(TIFF)
Figure S9 Blocking JAM-C boosts the Th2 cell response
and worsens the disease in BALB/c mice (Raw data of
Fig. 5). (A–C) Mice were inoculated with 16104 stationary phase
L. major promastigotes in the ear dermis and treated with H33 or
control antibody for 3 weeks. The parasite burden in infected ears
(A), draining lymph nodes (B), and spleens (C) were measured by
LDA. (D–E) Draining lymph nodes cells were restimulated with
UV-irradiated L. major for 72 hours, and the IL-4 (D) and IFN-c
(E) produced were measured. Data represent the mean 6 SEM of
5 mice per group. Data were analyzed by the unpaired Student’s t
test with *:p,0.05, ***: p,0.001. n.d. not-detectable. These
supporting informations are related to Fig. 5G, H, K and L.
(TIFF)
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